Education strategy for the implementation of oncology biosimilars essential for operational and patient safety in Alberta, Canada

Garg, Manju; Chatterjee, Ashraf; Chambers, Carole

doi:10.1177/10781552211007535

Cited by 1 publication

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oncology biosimilars are considered “look alike, sound alike” medications; thus, minimizing medication errors is essential. 22 Thus, patients, pharmacy staff, and nursing staff may realize clinical and economic value associated with a biosimilar portfolio, as it may reduce resources associated with administration. Economic value may also be realized by the institution/finance staff.…”

Section: Resultsmentioning

confidence: 99%

Clinical and Economic Value of a Biosimilar Portfolio to Stakeholders: An Integrative Literature Review

Fox,

Bernauer,

Stephens

et al. 2024

CEOR

View full text Add to dashboard Cite

Purpose While the value of individual biosimilars is evident, little is known about the value of a biosimilar portfolio beyond the cost savings between biosimilars and originators. Stakeholders may consider the value of a manufacturer’s biosimilar portfolio, especially when negotiating portfolio-based contracts or other rebate programs. However, little is known about what other types of value, in addition to financial benefits, decision-makers perceive regarding a manufacturer with a biosimilar portfolio compared to those without one. The objective of this integrative literature review was to describe a conceptual framework consisting of themes that may help define the value of a biosimilar portfolio. Methods An integrative literature review was conducted using Excerpta Medica Database (Embase) and Medical Literature Analysis and Retrieval System Online (MEDLINE). Grey literature searches of search engines, journals not indexed in Embase or MEDLINE, healthcare payers, health technology assessment bodies, value frameworks, and non-pharmaceutical industry analogs were also conducted. Eligible studies reported on the value of a biosimilar portfolio in decision-making by stakeholders. Apart from the literature, insights were gained from clinical experience and observation. Results No studies investigating biosimilar portfolio value were identified; however, several themes were identified that may help define the value of a biosimilar portfolio: Manufacturing; procurement, inventory, and storage; administration; education; and transaction costs. Several non-pharmaceutical industry analogs were identified: Product line length and single-supplier versus multiple-supplier procurement. Several themes were identified through other sources: Science credibility and research. Based on these themes, we developed a conceptual framework for biosimilar portfolio value. Conclusion To our knowledge, this is the first study to systematically assess and create a framework for biosimilar portfolio value. The conceptual framework described here could be tested to quantify the clinical and economic value associated with a biosimilar portfolio.

show abstract

Section: Resultsmentioning

confidence: 99%